These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 19483408

  • 1. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K.
    Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
    [Abstract] [Full Text] [Related]

  • 2. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K.
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
    [Abstract] [Full Text] [Related]

  • 3. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K.
    Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
    [Abstract] [Full Text] [Related]

  • 4. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K, Adachi K.
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [Abstract] [Full Text] [Related]

  • 5. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
    Hiestand PC, Rausch M, Meier DP, Foster CA.
    Prog Drug Res; 2008 Apr; 66():361, 363-81. PubMed ID: 18416311
    [Abstract] [Full Text] [Related]

  • 6. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
    Chiba K, Matsuyuki H, Maeda Y, Sugahara K.
    Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
    [Abstract] [Full Text] [Related]

  • 7. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
    Baumruker T, Billich A, Brinkmann V.
    Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
    [Abstract] [Full Text] [Related]

  • 8. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V.
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [Abstract] [Full Text] [Related]

  • 9. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [Abstract] [Full Text] [Related]

  • 10. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J.
    Proc Natl Acad Sci U S A; 2011 Jan 11; 108(2):751-6. PubMed ID: 21177428
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J, Hartung HP.
    Clin Neuropharmacol; 2010 Jan 11; 33(2):91-101. PubMed ID: 20061941
    [Abstract] [Full Text] [Related]

  • 12. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine.
    Mansoor M, Melendez AJ.
    Rev Recent Clin Trials; 2008 Jan 11; 3(1):62-9. PubMed ID: 18474015
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. FTY720: mechanism of action and potential benefit in organ transplantation.
    Brinkmann V.
    Yonsei Med J; 2004 Dec 31; 45(6):991-7. PubMed ID: 15627289
    [Abstract] [Full Text] [Related]

  • 15. FTY720: a most promising immunosuppressant modulating immune cell functions.
    Zhang Z, Schluesener HJ.
    Mini Rev Med Chem; 2007 Aug 31; 7(8):845-50. PubMed ID: 17692046
    [Abstract] [Full Text] [Related]

  • 16. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T, Brinkmann V.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A, Kihara Y, Chun J.
    J Neurol Sci; 2013 May 15; 328(1-2):9-18. PubMed ID: 23518370
    [Abstract] [Full Text] [Related]

  • 19. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW, Choi JW, Chun J.
    Arch Pharm Res; 2010 Oct 15; 33(10):1567-74. PubMed ID: 21052934
    [Abstract] [Full Text] [Related]

  • 20. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.
    Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, Wlachos A, Sobanov J, Kinnunen A, Baumruker T.
    Brain Pathol; 2009 Apr 15; 19(2):254-66. PubMed ID: 18540945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.